ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

Congress Session

About the speaker

Doctor Peter Kolkhof

BAYER HealthCare, Global Drug Discovery, Cardiology Research, Wuppertal (Germany)
0 follower

3 more presentations in this session

Potential therapeutic efficacy via avB3-integrin dependent interaction of developmental endothelial locus-1 (Del-1) after established angiotensin-II dependent hypertension

Speaker: Mr M. Amponsah-Offeh (Dresden, DE)

Thumbnail

Protective effects of renal denervation based on MRI assessment of the brain in patients with resistant hypertension

Speaker: Doctor A. Sukhareva (Tomsk, RU)

Thumbnail

24-month results and technical approach of catheter-based renal denervation in patients with resistant hypertension

Speaker: Associate Professor D. Maximkin (Moscow, RU)

Thumbnail

Access the full session

Recent advances in diagnosis/treatment of hypertension

Speakers: Doctor P. Kolkhof, Mr M. Amponsah-Offeh, Doctor A. Sukhareva, Associate Professor D. Maximkin
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

EHRA Premium Access

Hot topics in pacing and implantable cardioverter defibrillator.

5 April 2022

EHRA Premium Access

Hot topics in ventricular tachycardia.

5 April 2022

ESC Premium Access

The long non-coding RNA Heat4 is upregulated in heart failure and decreases the immune response of non-classical monocytes

27 August 2021

This platform is supported by

logo Novo Nordisk